Aims: Many sinus node disease (SND) patients suffer from atrial fibrillation (AF). Anti-arrhythmic drugs (AADs) are the therapeutic mainstay for AF prophylaxis. The PITAGORA trial has a multicentre, prospective, randomized, single blind design to compare amiodarone with Class IC AADs in patients who have an AF history and are paced for SND. Methods and results: Starting from January 2001, 176 patients received a Medtronic AT500 pacemaker. AADs were randomly assigned with a 3:2 ratio between Class III and Class IC. Randomization was stratified in order to assign two patients to amiodarone and one patient to sotalol every three Class III AAD patients. After a 5-month observational period, Ramp or Burst+ ATP therapies were enabled in a randomized way, maintained for 4 months, and then crossed over. Total follow-up period is 21 months. The primary long-term objective is to show the non-inferiority of IC AADs compared with amiodarone in terms of time to first occurrence of a composite endpoint (death, atrial cardioversion, hospitalizations due to AF or heart failure, or change of AADs). Data will be analysed on an intention-to-treat basis. The primary short-term objective is to compare Ramp vs. Burst+ efficacy in terminating atrial tachyarrhythmias treated by the device. Secondary endpoints are major clinical events, medication toxicity, symptoms, AF burden, and quality-of-life. Conclusion: Given the high morbidity and healthcare costs associated with AF, new therapeutic strategies are needed. The results of the PITAGORA trial may help in guiding AADs therapy and ATP programming in SND patients suffering from AF. © 2006 Oxford University Press.
Design and rationale of a randomized study to compare amiodarone and Class IC anti-arrhythmic drugs in terms of atrial fibrillation treatment efficacy in patients paced for sinus node disease: The PITAGORA trial / Gulizia, Michele; Mangiameli, Salvatore; Chiarandà, Giacomo; Spadola, Vincenzo; Di Giovanni, Nicolò; Colletti, Andrea; Bulla, Vincenzo; Circo, Antonio; Pensabene, Orazio; Vasquez, Ludovico; Vaccaro, Ignazio; Grammatico, Andrea; Boriani, G.; Biffi, M.; Orsola, S.; Bramanti, O.; Arrigo, Null; Butera, G.; Miranda, Null; Muscio, G. F.; Tosto, Null; Emanuele, V.; Guzzo, V.; Abele Aiello, Null; Evola, R.; Galvagna, G.; Vincenzo, S.; Ferrante, R.; Arestia, Null; Paternò-Arezzo, Null; Gambino, P.; Fratelli Parlapiano, Null; Giglia, S.; Elia, S.; Grassi, R.; Busà, G.; Papardo, Null; Gulizia, M.; Francese, G. M.; Luigi, S.; Currò, S.; Indelicato, V.; Lisi, F.; Coppola, A.; Cannizzaro, Null; Malluzzo, Null; Costanza, Null; Barone Lombardo, Null; Mangiameli, S.; Doria, Null; Garibaldi, Null; Mossuti, E.; Maltese, Null; Umberto, I.; Orazi, S.; Pavia, L.; Piemonte, Null; Puntrello, C.; Di Girolamo, Null; Antonio Abate, S.; Santini, M.; Ricci, R.; Filippo Neri, S.; Spadola, V.; Piccione, Null; Catalano, C.; Giovanni di Dio, S.; Vanaria, Null; Scalisi, Null; Tomaselli, Null; Vasco, C.; Battaglia, Null; Umberto, I.. - In: EUROPACE. - ISSN 1099-5129. - 8:4(2006), pp. 302-305. [10.1093/europace/eul003]
Design and rationale of a randomized study to compare amiodarone and Class IC anti-arrhythmic drugs in terms of atrial fibrillation treatment efficacy in patients paced for sinus node disease: The PITAGORA trial
Boriani, G.;
2006
Abstract
Aims: Many sinus node disease (SND) patients suffer from atrial fibrillation (AF). Anti-arrhythmic drugs (AADs) are the therapeutic mainstay for AF prophylaxis. The PITAGORA trial has a multicentre, prospective, randomized, single blind design to compare amiodarone with Class IC AADs in patients who have an AF history and are paced for SND. Methods and results: Starting from January 2001, 176 patients received a Medtronic AT500 pacemaker. AADs were randomly assigned with a 3:2 ratio between Class III and Class IC. Randomization was stratified in order to assign two patients to amiodarone and one patient to sotalol every three Class III AAD patients. After a 5-month observational period, Ramp or Burst+ ATP therapies were enabled in a randomized way, maintained for 4 months, and then crossed over. Total follow-up period is 21 months. The primary long-term objective is to show the non-inferiority of IC AADs compared with amiodarone in terms of time to first occurrence of a composite endpoint (death, atrial cardioversion, hospitalizations due to AF or heart failure, or change of AADs). Data will be analysed on an intention-to-treat basis. The primary short-term objective is to compare Ramp vs. Burst+ efficacy in terminating atrial tachyarrhythmias treated by the device. Secondary endpoints are major clinical events, medication toxicity, symptoms, AF burden, and quality-of-life. Conclusion: Given the high morbidity and healthcare costs associated with AF, new therapeutic strategies are needed. The results of the PITAGORA trial may help in guiding AADs therapy and ATP programming in SND patients suffering from AF. © 2006 Oxford University Press.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
